Three of the largest commodity-chemicals issuers in BASF’s, Dow’s, and LyondellBasell’s weight class reported first-quarter 2026 results inside a two-week window, and the language across all three is consistent: tighter capital spending, faster footprint rationalisation, and cost programmes ahead of any new-build narrative. For process-analytics vendors that sell into commodity polymers, intermediates, and basic chemicals, the readthrough is that the addressable spend is shifting from greenfield analyser packages toward brownfield retrofits, sustainment, and consolidation work on existing assets.

This piece reads across the three releases on what each issuer said about capex, footprint, and operational priorities for 2026, and what that mix implies for analyser demand in the commodity-chemicals end market.

BASF: South China Verbund up, capex below depreciation

BASF reported Q1 2026 sales of EUR 16.0 billion on April 30, down EUR 488 million from the prior-year quarter, with adverse currency effects and slightly lower prices doing most of the work. EBITDA before special items was EUR 2.36 billion against EUR 2.50 billion a year earlier. CFO Dirk Elvermann’s framing in the release was that, absent more than EUR 100 million of currency headwinds, EBITDA before special items would have matched the prior-year level.

Volume growth was broad. Nearly all segments recorded higher sales volumes except Surface Technologies, and BASF attributed part of the volume strength to the start-up of its new Verbund site in Zhanjiang, southern China - a project that had been a multi-year capex anchor and now sits in the operating base rather than the project pipeline. EBITDA before special items declined year-on-year at Chemicals, Agricultural Solutions, and Nutrition & Care, improved at Surface Technologies and Materials, and matched the prior-year level at Industrial Solutions.

On capex, the picture matters more than the quarter. BASF has guided to roughly EUR 3 billion of capital expenditures in 2026, below the company’s depreciation and amortisation run rate, and to roughly EUR 13 billion across 2026 to 2029. That sustains the message Markus Kamieth and Elvermann delivered at the October 2025 capital-markets update: the heavy capex phase tied to the South China Verbund is behind the company, and free-cash discipline is the priority through to the next strategic cycle. BASF held its 2026 EBITDA-before-special-items range at EUR 6.2 to 7.0 billion and free cash flow at EUR 1.5 to 2.3 billion.

LyondellBasell: portfolio transformation substantially complete

LyondellBasell reported Q1 2026 sales and operating revenues of $7.20 billion and EBITDA of $568 million, or $615 million excluding identified items. EBITDA recovered close to 50% sequentially from the fourth quarter of 2025, with the Olefins and Polyolefins - Americas segment effectively doubling as lower feedstock costs combined with a recovery in integrated polyethylene margins. Intermediates and Derivatives saw stronger propylene-oxide margins, partly offset by delayed asset restarts and outages. Q1 2026 capital expenditure was $269 million.

The structural news in the release is the footprint. CEO Peter Vanacker described the company’s portfolio transformation as substantially complete. Over the past 18 months LyondellBasell has ceased its Houston refining operations, divested the Ethylene Oxide and Derivatives business, and closed the sale of four European assets early in the second quarter of 2026. Roughly 3,000 positions have come out since year-end 2024. Capital spending guidance for the year was framed in terms of discipline rather than dollar targets, with the cash balance of $2.6 billion and total liquidity of $7.3 billion underlining a preserve-cash posture.

For analyser vendors, the salient point is that LyondellBasell’s installed base in Europe is now materially smaller than it was at the start of 2025, and the remaining assets in the Americas and the joint-venture portfolio are being asked to run harder. Sustainment work on existing instruments and consolidation of monitoring functions onto retained sites is where the budget is, not on new analyser fleets.

Dow: cost programme, leadership change, $2.5 billion capex

Dow reported Q1 2026 net sales of $9.8 billion, down 6% year-on-year, with operating EBITDA of $873 million against $944 million in the prior-year quarter. Volume grew 3% sequentially, led by Packaging and Specialty Plastics. The segment posted $4.9 billion of sales and $208 million of operating EBIT; Industrial Intermediates and Infrastructure ran a $118 million operating-EBIT loss on weaker pricing; Performance Materials and Coatings was roughly flat on sales at $2.1 billion with $117 million of operating EBIT. GAAP net loss was $445 million, with operating EPS of negative 14 cents.

CEO Jim Fitterling framed the quarter around a programme called “Transform to Outperform,” targeting around $1 billion of structural cost savings and described in the release as a push to simplify operations, reengineer processes, and modernise customer-facing work. Karen Carter will take over as CEO on July 1, 2026, with Fitterling moving to executive chair. Full-year 2026 capital spending is guided to roughly $2.5 billion, with Q1 spending at $503 million. Q2 revenue was indicated at roughly $12 billion and Q2 EBITDA at roughly $2 billion.

Dow’s $1 billion cost programme is precisely the kind of mandate that has historically produced retrofit demand for inline analysers and asset-monitoring tools, on the operational-excellence side of the budget rather than the engineering-and-construction side. Whether that translates into orders for Raman, NIR, gas-phase mass-spec, or third-party process-data platforms depends on whether the savings are concentrated in headcount, energy, and feedstock yield - and on how new leadership chooses to balance maintenance capex against discretionary instrumentation upgrades.

What it adds up to for process analytics

Cross-reading the three releases, four themes recur:

  • Capex envelope is small and shrinking. BASF below D&A at roughly EUR 3 billion, Dow at roughly $2.5 billion, LyondellBasell explicitly disciplined with no headline target. None of the three is in a build phase.
  • Footprint is being trimmed. LyondellBasell’s European asset sales and refining exit are the clearest example, but Dow’s simplification programme implies further European and intermediates-side decisions, and BASF has been pruning legacy German operations alongside the South China start-up.
  • Cost programmes are explicit and large. Dow’s $1 billion target is named, BASF’s EUR 2.3 billion run-rate cost-savings programme is past the halfway mark, and LyondellBasell’s headcount actions are already in the base.
  • Volume growth, where it exists, is in retained assets. Newly started Verbund capacity at Zhanjiang and consolidated polyethylene production in the LyondellBasell Americas base are running, while the divested or shuttered European footprint is no longer in the mix.

For analyser vendors selling Raman, NIR, gas chromatography, online mass spec, and process-data infrastructure, the implication is that 2026 demand from this customer set will look much more like a brownfield mix than a greenfield one. The order book is more likely to come from sustainment, debottlenecking, energy-yield projects, and consolidation of monitoring functions onto retained assets, and less likely to come from analyser packages tied to new units. Operational-excellence-funded retrofit work - the kind of project justified on yield or reliability rather than on a project finance basis - becomes the more relevant pipeline. That is a different sales motion than chasing engineering-and-construction packages, and it shapes which vendors and which product categories are best positioned in the commodity-chemicals end market through the rest of 2026.

Investors triangulating instrument-vendor exposure should treat these three releases as a coherent signal: the analytical-instruments commentary from Thermo Fisher on academic and government softness, and the process-analytics commentary from Mettler-Toledo on semiconductor and bioprocessing strength, sit alongside a commodity-chemicals customer base that is not currently in a capex-led growth phase.